CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) CEO Jerrell Shelton sold 28,800 shares of CryoPort stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the sale, the chief executive officer directly owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. This trade represents a 2.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CryoPort Trading Up 0.9%
Shares of CYRX traded up $0.13 during midday trading on Tuesday, reaching $14.95. The stock had a trading volume of 624,658 shares, compared to its average volume of 591,327. The company has a market capitalization of $757.20 million, a price-to-earnings ratio of -16.61 and a beta of 1.89. The company’s 50-day moving average is $15.47 and its 200 day moving average is $11.95. CryoPort, Inc. has a 12-month low of $7.61 and a 12-month high of $16.89.
CryoPort (NASDAQ:CYRX – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $48.97 million for the quarter, compared to analysts’ expectations of $48.18 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. Research analysts forecast that CryoPort, Inc. will post -0.85 EPS for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Stock Report on CYRX
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Basepoint Wealth LLC bought a new stake in CryoPort during the 4th quarter valued at $34,000. Tower Research Capital LLC TRC grew its holdings in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares during the last quarter. Creative Planning bought a new stake in CryoPort in the 2nd quarter worth $96,000. Quadrature Capital Ltd purchased a new position in shares of CryoPort in the fourth quarter valued at about $97,000. Finally, State of Wyoming increased its position in shares of CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after acquiring an additional 3,301 shares during the period. Institutional investors own 92.90% of the company’s stock.
About CryoPort
CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.
CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.
Further Reading
- Five stocks we like better than CryoPort
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.
